The biotech stock is feeling the heat from an indictment of a former consultant.
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?